- 专利标题： GENERATION OF ANTIBODIES TO TUMOR ANTIGENS AND GENERATION OF TUMOR SPECIFIC COMPLEMENT DEPENDENT CYTOTOXICITY BY ADMINISTRATION OF ONCOLYTIC VACCINIA VIRUS
-
申请号： US15892247申请日： 2018-02-08
-
公开(公告)号： US20180214538A1公开(公告)日： 2018-08-02
- 发明人: David KIRN , John BELL , Caroline BREITBACH , Anne MOON , Tae-Ho HWANG , Yu Kyoung LEE , Mi-kyung KIM
- 申请人： SILLAJEN BIOTHERAPEUTICS, INC. , SILLAJEN, INC.
- 申请人地址： US CA San Francisco KR Busan
- 专利权人： SILLAJEN BIOTHERAPEUTICS, INC.,SILLAJEN, INC.
- 当前专利权人： SILLAJEN BIOTHERAPEUTICS, INC.,SILLAJEN, INC.
- 当前专利权人地址： US CA San Francisco KR Busan
- 主分类号： A61K39/285
- IPC分类号： A61K39/285 ; A61K35/26
摘要：
The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
公开/授权文献
信息查询
